Deep Dive Into NewAmsterdam Pharma Stock: Analyst …

Jan 24, 2025 · Price Targets: Analysts provide insights into price targets, offering estimates for the future value of NewAmsterdam Pharma's stock. This comparison reveals trends in analysts' …

CouponFollow Extension

$35
OFF

NewAmsterdam Pharma Stock: A Deep Dive Into Analyst ... - Nasdaq

3 weeks from now

Nov 11, 2024 · Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $35.2, along with a high estimate of $37.00 and a low estimate …

nasdaq.com

$36
OFF

Forecasting The Future: 5 Analyst Projections For NewAmsterdam …

3 weeks from now

Dec 5, 2024 · Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $36.2, a high estimate of $37.00, and a low estimate of …

nasdaq.com

$37.67
OFF

Jefferies Sticks To Their Buy Rating For NewAmsterdam Pharma …

3 weeks from now

Nov 19, 2024 · NewAmsterdam Pharma Company has an analyst consensus of Strong Buy, with a price target consensus of $37.67. See the top stocks recommended by analysts >> The …

businessinsider.com

$0.26
OFF

NewAmsterdam Pharma (NASDAQ:NAMS) Now Covered By …

3 weeks from now

Dec 30, 2024 · Check Out Our Latest Report on NewAmsterdam Pharma. NewAmsterdam Pharma Price Performance. Shares of NASDAQ:NAMS traded down $0.26 during trading on …

marketbeat.com

$481
OFF

NewAmsterdam Pharma: Cholesterol Drug Treatment With …

3 weeks from now

Jul 5, 2024 · NewAmsterdam Pharma Company had cash of $481.1 million as of March 31, 2024. ... Read why I feel NAMS is an interesting biotech stock to look into. ... My service offers a …

seekingalpha.com

$35
OFF

What 4 Analyst Ratings Have To Say About NewAmsterdam Pharma

3 weeks from now

Nov 7, 2024 · Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $35.0, a high estimate of $37.00, and a low estimate of …

nasdaq.com

$40.00
OFF

NAMS - Stock Quotes For NAMS Ent Holdg, NASDAQ: NAMS …

3 weeks from now

Deep Dive Into NewAmsterdam Pharma Stock: Analyst Perspectives (8 Ratings) Benzinga · 2d ago. NewAmsterdam Pharma Price Target Maintained With a $40.00/Share by RBC Capital. …

webull.com

$2
OFF

NewAmsterdam Pharma's SWOT Analysis: Obicetrapib Stock Shows …

3 weeks from now

4 days ago · NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS), a biopharmaceutical company with a market capitalization of $2.3 billion focused on developing cardiovascular …

investing.com

$33.75
OFF

Expert Ratings For NewAmsterdam Pharma - Nasdaq

3 weeks from now

Sep 23, 2024 · Analysts have set 12-month price targets for NewAmsterdam Pharma, revealing an average target of $33.75, a high estimate of $37.00, and a low estimate of $31.00.

nasdaq.com

$491.76
OFF

Vertex Pharmaceuticals Stock: A Deep Dive Into Analyst ... - Nasdaq

3 weeks from now

3 days ago · Analysts have set 12-month price targets for Vertex Pharmaceuticals, revealing an average target of $491.76, a high estimate of $586.00, and a low estimate of $408.00.

nasdaq.com

$29
OFF

Pfizer Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)

3 weeks from now

5 days ago · Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $29.5, along with a high estimate of $33.00 and a low estimate …

nasdaq.com

FAQs about Deep Dive Into NewAmsterdam Pharma Stock: Analyst … Coupon?

Is newamsterdam pharma company a good buy?

NewAmsterdam Pharma Company has an analyst consensus of Strong Buy, with a price target consensus of $37.67. The company has a one-year high of $26.35 and a one-year low of $8.90. Currently, NewAmsterdam Pharma Company has an average volume of 380.2K. ...

Is newamsterdam Pharma (NAMS) a good biotech?

Learn More » NewAmsterdam Pharma Company N.V. ( NASDAQ: NAMS) is a biotech that should be on all traders and investors' radar. The reason why I state that is because it is gearing up to report data from several studies over the next 1-year period. ...

Who is newamsterdam Pharma?

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Return vs Industry: NAMS exceeded the US Biotechs industry which returned 8.2% over the past year. ...

How much cash does newamsterdam Pharma have?

According to the 10-Q SEC Filing, NewAmsterdam Pharma Company N.V. had cash of $481.1 million as of March 31, 2024. The reason for the cash on hand is because of an upsized public offering of 5,871,909 ordinary shares of its common stock and 4,736,841 pre-funded warrants. ...

What risks should investors consider before investing in newamsterdam?

There are several risks that investors should be aware of before investing in NewAmsterdam. The first risk to consider would be regarding the ongoing phase 3 BROOKLYN study, which is using obicetrapib for the treatment of patients with HeFH. ...

How much cash does newamsterdam make per quarter?

Its cash burn is $56.9 million per quarter, which should provide a cash runway of a couple of years, though the company apparently hasn't itself provided that figure. There are several risks that investors should be aware of before investing in NewAmsterdam. ...